Kevin Flowers's Email & Phone

For more than a decade, Kevin M. Flowers, Ph.D. has successfully protected billion-dollar-per-year products for leading pharmaceutical and biotechnology companies in high-stakes patent-infringement litigation. As a first-chair trial attorney, he relies on his sure and rapid understanding of the technology as a Ph.D. scientist, his years of teaching experience before he became an attorney, and his trial instincts (developed very early in his career and continually honed ever since) to consistently persuade judges and juries to rule in his clients? favor on complex legal and scientific issues. On the weekends, Dr. Flowers is also an accomplished competitive triathlete, runner, cyclist, and cross-country skier. representative experience Dr. Flowers has also been successful in the following cases: * Amgen* v. Hoechst Marion Roussel (D. Mass.) (recombinant EPO) * Schering v. Geneva Pharmaceuticals et al.* (D.N.J.) (generic versions of Claritin®) * Cell Genesys Inc. v. Applied Research Systems* and Applied Research Systems* v. TKT (N.D. Cal.) (patents covering methods of endogenous gene activation) * Rogers et al. v. Zambryski et al. and Fraley et al. v. Zambryski et al. (U.S. PTO) (interferences involving pioneering claims for genetically modified plants) * Danisco* v. Novozymes (S.D. N.Y.) (patents covering recombinant food-processing enzymes) * Hyseq* v. Affymetrix and Affymetrix* v. Hyseq (N.D. Cal.) (patents covering gene chips) * Default Proof Credit Card System v. Home Depot* et al. (S.D. Fla.) and RealSource Communications v. Home Depot* et al. (E.D. Tex.) (retail gift-card systems) * Brooklyn Bottling v. Jamaica Drink* (S.D. Fla.) (trademark infringement) * EMKG v. Bisco, Inc. et al.* (N.D. Tex.) (dental composite products) Dr. Flowers is currently handling the following cases: * Life Technologies Corp. v. Illumina, Inc., et al.* (D. Del.) (patents covering DNA amplification and sequencing systems): We represent Illumina in this case in which Life Tech and Illumina are each alleging infringement of multiple patents covering systems and methods for DNA amplification and detection by the other party's next-generation DNA sequencing systems. The action is scheduled to go to trial in November 2011. * Eli Lilly and Co.* v. Synthon Pharmaceuticals, Inc. (S.D. Ind.) (patents covering Adcirca®): We represent Eli Lilly, which holds several patents covering the active ingredient in the drug Adcirca®, in this ANDA case against Synthon, which seeks to market a generic version of Adcirca®. * Illumina, Inc.* v. Complete Genomics, Inc. (D. Del.) (patents covering DNA sequencing methods and systems): We represent Illumina in this case in which Illumina is alleging infringement of multiple patents covering methods, systems and products used in high-throughput DNA sequencing systems. * Yeda Research and Development* v. Abbott GmbH (N.D. Ill.): We represent Yeda in this Section 146 action involving Abbott's patent and Yeda's pending patent application directed to recombinant TNF-binding proteins." Background and Credentials Dr. Flowers received his law degree from The Ohio State University Moritz College of Law, where he was a Managing Editor and contributing author for the Ohio State Journal on Dispute Resolution. While in law school, he worked full-time as a law clerk in a high-profile criminal-defense practice. Dr. Flowers received his undergraduate degree in Biology and a Master's degree in Health Education from The Ohio State University, and his Ph.D. from the Cellular and Molecular Physiology program at the Pennsylvania State University College of Medicine and Graduate School. His scientific research led to eleven peer-reviewed scientific publications.